The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are:
* Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment?
* What medical problems do participants have when receiving Glofitamab treatment?
In this investigator-initiated, single-arm clinical trial, participants will:
* Receive Glofitamab treatment as per the instructions in the package insert.
* Visit the clinic as instructed for checkups and tests.